InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,485.20
(
0.99%
)
US TECH 100
19,435.99
(
1.40%
)
Dow Jones
38,791.34
(
0.52%
)
Brent Oil
83.97
(
2.24%
)
Bitcoin
66,751.08
(
0.17%
)
Post# of 21475
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Goodbuddy4863

Send PM Follow Ignore
Followers 644
Posts 38176
Boards Moderated 1
Alias Born 03/29/2003

Goodbuddy4863

Re: Goodbuddy4863 post# 11635

Monday, 10/27/2014 1:37:26 AM

Monday, October 27, 2014 1:37:26 AM

Post# of 21475
GW Pharmaceuticals Receives Investigational New Drug (IND) From FDA for Phase 2/3 Clinical Trial of Epidiolex(R) in the Treatment of Dravet Syndrome:

http://www.marketwatch.com/story/gw-pharmaceuticals-receives-investigational-new-drug-ind-from-fda-for-phase-23-clinical-trial-of-epidiolexr-in-the-treatment-of-dravet-syndrome-2014-05-07

I believe they are in Phase 3 of this Orphaned Status drug [Epidiolex(R]confirmed by the Food and Drug Administration.

http://www.projectcbd.org/news/fda-grants-orphan-drug-status-to-gws-epidiolex-2/
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up